Additionally, we analyze its potential as multidisease biomarker, crosstalk mediator, and therapeutic target, providing new strategies and perspectives for drug research and the prevention and treatment of various diseases
The decision to continue, adjust, or discontinue Ozempic should be made collaboratively, weighing the benefits of improved glycaemic control against the impact of gastrointestinal adverse effects on patient wellbeing
Offering Flu, Whooping Cough, Shingles, Mump, Measels and so much more
The resulting weight lossoften 15-20% of body weight with higher doses approved for obesity (Wegovy/Zepbound) and 5-10% with lower doses for diabetes (Ozempic/Mounjaro)can actually improve several cardiovascular risk factors